Astec LifeSciences (ASTEC) Fundamentals 2026 — Revenue Analysis | SniperIQ
Astec LifeSciences (ASTEC) is a India-listed Basic Materials company in Agricultural Inputs with a market capitalization of ₹1,499 Crore, trading at ₹672.75 on the NSE. This SniperIQ fundamentals page covers Astec LifeSciences's valuation, profitability (net margin -18.1%), revenue (₹448 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Astec LifeSciences's market cap?
Astec LifeSciences (ASTEC) has a market capitalization of approximately ₹1,499 Crore, trading at ₹672.75 on the NSE. Market cap moves with the live share price.
What is Astec LifeSciences's P/E ratio?
Astec LifeSciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Astec LifeSciences?
Astec LifeSciences runs a net profit margin of -18.1%, a gross margin of 15.3%, and an operating margin of -11.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Astec LifeSciences generate?
Astec LifeSciences reported revenue of ₹448 Crore for fiscal year 2026, with net income of -₹81 Crore and earnings per share (EPS) of -37.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Astec LifeSciences pay a dividend?
Astec LifeSciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Astec LifeSciences financially healthy?
Astec LifeSciences carries a debt-to-equity ratio of 1.15x and a current ratio of 0.89x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Astec LifeSciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Astec LifeSciences (ASTEC) the key facts are: market cap ₹1,499 Crore, revenue ₹448 Crore, 52-week range 513.4-941.75. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Astec LifeSciences's full fundamentals live
Get Astec LifeSciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.